Curaleaf Sends Letter to Aurora Shareholders Urging Them to Accept Hostile Takeover Bid
Curaleaf (CURA) urged Aurora (ACB) shareholders to accept its hostile takeover bid, offering a 45% premium. Curaleaf claims the deal would create a global cannabis leader with $1.5B revenue and $350M EBITDA. Aurora's management advises shareholders to reject the offer, citing inadequate value and risks.
How this was made

The 30-second read
Why it matters
The bid intensifies competition in the cannabis industry and may reshape market share, but the outcome remains uncertain.
Market read
The hostile takeover narrative adds volatility to both stocks and signals broader consolidation trends in the sector.
What to watch
Regulatory risks and financing constraints for Curaleaf could derail the transaction.
Background
Curaleaf, a U.S.-listed cannabis operator, launched a hostile bid for Aurora Cannabis, a Canadian‑listed peer. The bid was announced in August; this article reports a new shareholder letter urging acceptance and Aurora's board rejection.
Ticker impact
Aurora Cannabis rejected Curaleaf's hostile offer and warned shareholders to vote against it.
downside pressure as investors fear a protracted battle and possible lower valuation.
Board opposition signals higher cost of acquisition; market may discount Aurora shares.
Market effects
Consolidation pressure in the North American cannabis sector.
U.S. and Canadian cannabis markets may see increased M&A activity.
Potential creation of a larger global cannabis player.
Counterpoint
Deal could be overvalued; Aurora may pursue alternative growth paths.
Key entities
- CompanyCuraleaf Holdings, Inc.
U.S. cannabis operator pursuing acquisition.
- CompanyAurora Cannabis Inc.
Canadian cannabis producer resisting the takeover.



